NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
76282-0710-67 | 76282-0710 | Lanreotide acetate | Lanreotide Acetate | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
69656-0101-02 | 69656-0101 | Rolapitant | Varubi | 90.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 7, 2015 | Oct. 31, 2021 | No Longer Used |
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct. 25, 2022 | In Use | |
69468-0151-04 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
69468-0151-10 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
69468-0151-20 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
00115-1261-01 | 00115-1261 | Anastrozole | Anastrozole | Hormonal Therapy | Aromatase Inhibitor | Oral | June 5, 2013 | Aug. 26, 2013 | No Longer Used | ||
00115-1261-03 | 00115-1261 | Anastrozole | Anastrozole | Hormonal Therapy | Aromatase Inhibitor | Oral | June 5, 2013 | Aug. 26, 2013 | No Longer Used | ||
00115-1261-08 | 00115-1261 | Anastrozole | Anastrozole | Hormonal Therapy | Aromatase Inhibitor | Oral | June 5, 2013 | Aug. 26, 2013 | No Longer Used | ||
00115-1261-10 | 00115-1261 | Anastrozole | Anastrozole | Hormonal Therapy | Aromatase Inhibitor | Oral | June 5, 2013 | Aug. 26, 2013 | No Longer Used |
Found 10,000 results in 16 milliseconds — Export these results